SG11201903456WA - Piperidine derivatives as inhibitors of ubiquitin specific protease 7 - Google Patents
Piperidine derivatives as inhibitors of ubiquitin specific protease 7Info
- Publication number
- SG11201903456WA SG11201903456WA SG11201903456WA SG11201903456WA SG11201903456WA SG 11201903456W A SG11201903456W A SG 11201903456WA SG 11201903456W A SG11201903456W A SG 11201903456WA SG 11201903456W A SG11201903456W A SG 11201903456WA SG 11201903456W A SG11201903456W A SG 11201903456WA
- Authority
- SG
- Singapore
- Prior art keywords
- almac
- craigavon
- house
- seagoe
- armagh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIPO I PCT omit IIl °nolo olomll oimIE (10) International Publication Number WO 2018/073602 Al (51) International Patent Classification: C07D 401/04 (2006.01) C07D 473/00 (2006.01) C07D 401/06 (2006.01) C07D 487/04 (2006.01) CO7D 401/14 (2006.01) CO7D 491/04 (2006.01) CO7D 403/04 (2006.01) CO7D 513/04 (2006.01) CO7D 471/04 (2006.01) A61K 31/506 (2006.01) CO7D 471/10 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/GB2017/053175 (22) International Filing Date: 20 October 2017 (20.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617758.6 20 October 2016 (20.10.2016) GB (71) Applicant: ALMAC DISCOVERY LIMITED [GB/GB]; Almac House, 20 Seagoe Industrial Estate, Craigavon BT63 5QD (GB). (72) Inventors: O'DOWD, Colin; c/o Almac Discovery Limit- ed, Almac House, 20 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). HARRISON, Tim; c/o Almac Discovery Limited, Almac House, 20 Seagoe Industrial Es- tate, Craigavon Armagh BT63 5QD (GB). HEWITT, Pe- ter; c/o Almac Discovery Limited, Almac House, 20 Sea- goe Industrial Estate, Craigavon Armagh BT63 5QD (GB). ROUNTREE, Shane; c/o Almac Discovery Limited, Al- mac House, 20 Seagoe Industrial Estate, Craigavon Ar- magh BT63 5QD (GB). HUGUES, Miel; c/o Almac Dis- covery Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). BURKAMP, Frank; c/o Almac Discovery Limited, Almac House, 20 Seagoe In- dustrial Estate, Craigavon Armagh BT63 5QD (GB). JOR- DAN, Linda; c/o Almac Discovery Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). HELM, Matthew; c/o Almac Discovery Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon Ar- magh BT63 5QD (GB). BROCCATELLI, Fabio; c/o Al- mac Discovery Limited, Almac House, 20 Seagoe Indus- trial Estate, Craigavon Armagh BT63 5QD (GB). CRAW- FORD, James John; c/o Almac Discovery Limited, Al- mac House, 20 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). GAZZARD, Lewis; c/o Almac Discov- ery Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). WERTZ, Ingrid; c/ o Almac Discovery Limited, Almac House, 20 Seagoe In- dustrial Estate, Craigavon Armagh BT63 5QD (GB). LEE, O Wendy; c/o Almac Discovery Limited, Almac House, 20 N O Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). (74) Agent: BOULT WADE TENNANT; Verulam Gardens, 70 Gray's Inn Road, London Greater London WC1X 8BT (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) O (57) : The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods 0 of use thereof. (54) Title: PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1617758.6A GB201617758D0 (en) | 2016-10-20 | 2016-10-20 | Pharmaceutical compounds |
PCT/GB2017/053175 WO2018073602A1 (en) | 2016-10-20 | 2017-10-20 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903456WA true SG11201903456WA (en) | 2019-05-30 |
Family
ID=57738053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903456WA SG11201903456WA (en) | 2016-10-20 | 2017-10-20 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10766903B2 (en) |
EP (2) | EP3529241B1 (en) |
JP (2) | JP7073359B2 (en) |
KR (1) | KR20190069529A (en) |
CN (1) | CN110088096A (en) |
AU (1) | AU2017346516B2 (en) |
BR (1) | BR112019007977A2 (en) |
CA (1) | CA3040805A1 (en) |
DK (1) | DK3529241T3 (en) |
ES (1) | ES2914284T3 (en) |
GB (1) | GB201617758D0 (en) |
IL (1) | IL266146A (en) |
MX (2) | MX2019004450A (en) |
RU (1) | RU2019115115A (en) |
SG (1) | SG11201903456WA (en) |
WO (1) | WO2018073602A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
CA3072353A1 (en) * | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Novel usp7 inhibitors for treating multiple myeloma |
GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
UY38291A (en) * | 2018-07-05 | 2020-06-30 | Servier Lab | NEW AMINO-PYRIMIDONYL DERIVATIVES A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS |
UY38423A (en) * | 2018-10-19 | 2021-02-26 | Servier Lab | NEW AMINO-PYRIMIDONIL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CN109912598B (en) * | 2019-03-27 | 2022-09-13 | 四川大学华西医院 | Nucleoside derivative for preventing and treating inflammatory reaction and application thereof |
CN111808105B (en) * | 2019-04-11 | 2023-09-08 | 四川科伦博泰生物医药股份有限公司 | Pyrimidinone pyrazolo compound containing fused ring group, preparation method and application thereof |
CN113423709B (en) * | 2019-04-11 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | Triazinone imidazole compound and medical application thereof |
CN113087724B (en) * | 2020-01-08 | 2024-01-19 | 四川科伦博泰生物医药股份有限公司 | Isothiazolopyrimidinone compounds, pharmaceutical compositions containing the same and uses thereof |
CN112608320B (en) * | 2020-01-16 | 2023-03-17 | 中国药科大学 | Piperidine compound and preparation method and medical application thereof |
GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
US20230087388A1 (en) | 2020-02-28 | 2023-03-23 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
CN112047933B (en) * | 2020-10-15 | 2022-06-14 | 郑州大学 | Quinazolinone USP7 inhibitor and preparation method and application thereof |
CN113336714A (en) * | 2021-06-25 | 2021-09-03 | 山东大学 | Compound and preparation method and application thereof |
WO2022272133A2 (en) * | 2021-06-25 | 2022-12-29 | Stablix, Inc. | Protein stabilizing compounds containing usp7 ligands |
CA3225596A1 (en) * | 2021-07-20 | 2023-01-26 | Sara BUHRLAGE | Inhibitors targeting ubiquitin specific protease 7 (usp7) |
GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
CN114507278B (en) * | 2022-01-27 | 2023-04-25 | 苏州大学 | UFM1-Lys-TAMRA probe and synthesis method thereof |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO111096A0 (en) | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
ZA986594B (en) | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
AU2003301095A1 (en) | 2002-12-23 | 2004-07-22 | Merck And Co., Inc. | 4(spiropiperidinyl)methyl substituted pyrrolidines as modulators of chemokine receptor activity |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
JP4787529B2 (en) | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | Pharmaceutical composition |
EP1765348B1 (en) | 2004-06-18 | 2016-08-03 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP1915377A1 (en) | 2005-07-22 | 2008-04-30 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
EP1749822B1 (en) | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
CA2638787A1 (en) | 2006-02-16 | 2007-08-23 | Takeda Pharmaceutical Company Limited | Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension |
JP5406722B2 (en) | 2006-10-16 | 2014-02-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Substituted sulfonamide derivatives as bradykinin 1 receptor modulators |
US7875613B2 (en) | 2006-10-30 | 2011-01-25 | Hybrigenics Sa | Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
FR2911138B1 (en) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | NOVEL N, N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS INHIBITORS OF IKK |
WO2009074487A1 (en) | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Inhibitors of stearoyl-coa desaturase |
ES2531398T3 (en) | 2008-02-22 | 2015-03-13 | Msd Kk | New aminopyridine derivatives that have a selective inhibitory action on Aurora A |
AU2009272486A1 (en) | 2008-07-18 | 2010-01-21 | Takeda Pharmaceutical Company Limited. | Benzazepine derivatives and their use as hstamine H3 antagonists |
RU2011105768A (en) | 2008-08-01 | 2012-09-10 | Биокрист Фармасьютикалз, Инк. (Us) | PIPERIDINE DERIVATIVES AS JAKЗ INHIBITORS |
EP2331518A1 (en) | 2008-08-22 | 2011-06-15 | Evotec AG | New bradykinin b1 antagonists |
EP2208725A1 (en) | 2009-01-13 | 2010-07-21 | Hybrigenics S.A. | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
US20120264735A1 (en) | 2009-12-21 | 2012-10-18 | Jonathan Young | Tyrosine kinase inhibitors |
US20110177105A1 (en) | 2010-01-15 | 2011-07-21 | Roman Lopez | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
TWI503323B (en) | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | Tricyclic compounds and pbk inhibitors containing the same |
CN103025725B (en) | 2010-08-10 | 2015-09-16 | 安斯泰来制药有限公司 | Heterogeneous ring compound |
JP2012072067A (en) | 2010-09-28 | 2012-04-12 | Astellas Pharma Inc | Nitrogen containing aromatic heterocyclic compound |
GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
GEP201706608B (en) | 2011-10-07 | 2017-01-25 | Takeda Pharmaceuticals Co | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases |
US8969341B2 (en) | 2011-11-29 | 2015-03-03 | Novartis Ag | Pyrazolopyrrolidine compounds |
MX347917B (en) | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof. |
WO2014045101A1 (en) * | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9763957B2 (en) | 2013-07-18 | 2017-09-19 | Novartis Ag | Autotaxin inhibitors |
JPWO2015046193A1 (en) | 2013-09-25 | 2017-03-09 | 塩野義製薬株式会社 | Aromatic heterocyclic amine derivatives having TRPV4 inhibitory activity |
RU2021102805A (en) | 2014-12-05 | 2021-02-12 | Эррэй Биофарма Инк. | 4,6-SUBSTITUTED PYRAZOLO [1,5-a] PYRAZINES AS INHIBITORS OF JANUS KINASE |
MA41291A (en) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER |
TWI770525B (en) | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors |
US9938300B2 (en) * | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
WO2016126929A1 (en) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2016150800A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Usp7 inhibitor compounds and methods of use |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201612938D0 (en) | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
JP7466308B2 (en) | 2016-09-20 | 2024-04-12 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Compositions and methods for identifying, evaluating, preventing, and treating AML using USP10 biomarkers and modulators - Patents.com |
-
2016
- 2016-10-20 GB GBGB1617758.6A patent/GB201617758D0/en not_active Ceased
-
2017
- 2017-10-20 MX MX2019004450A patent/MX2019004450A/en unknown
- 2017-10-20 WO PCT/GB2017/053175 patent/WO2018073602A1/en unknown
- 2017-10-20 EP EP17790829.0A patent/EP3529241B1/en active Active
- 2017-10-20 CA CA3040805A patent/CA3040805A1/en not_active Withdrawn
- 2017-10-20 US US16/343,917 patent/US10766903B2/en active Active
- 2017-10-20 EP EP22157226.6A patent/EP4026832A1/en not_active Withdrawn
- 2017-10-20 JP JP2019520996A patent/JP7073359B2/en active Active
- 2017-10-20 CN CN201780077139.8A patent/CN110088096A/en not_active Withdrawn
- 2017-10-20 DK DK17790829.0T patent/DK3529241T3/en active
- 2017-10-20 SG SG11201903456WA patent/SG11201903456WA/en unknown
- 2017-10-20 BR BR112019007977A patent/BR112019007977A2/en not_active Application Discontinuation
- 2017-10-20 RU RU2019115115A patent/RU2019115115A/en unknown
- 2017-10-20 ES ES17790829T patent/ES2914284T3/en active Active
- 2017-10-20 AU AU2017346516A patent/AU2017346516B2/en not_active Revoked
- 2017-10-20 KR KR1020197014463A patent/KR20190069529A/en not_active Application Discontinuation
-
2019
- 2019-04-16 MX MX2021012589A patent/MX2021012589A/en unknown
- 2019-04-18 IL IL266146A patent/IL266146A/en unknown
-
2022
- 2022-05-11 JP JP2022077871A patent/JP2022106953A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP7073359B2 (en) | 2022-05-23 |
DK3529241T3 (en) | 2022-07-11 |
EP4026832A1 (en) | 2022-07-13 |
AU2017346516B2 (en) | 2021-10-14 |
GB201617758D0 (en) | 2016-12-07 |
WO2018073602A1 (en) | 2018-04-26 |
EP3529241A1 (en) | 2019-08-28 |
RU2019115115A3 (en) | 2020-11-24 |
MX2021012589A (en) | 2021-11-12 |
JP2019535664A (en) | 2019-12-12 |
MX2019004450A (en) | 2019-08-05 |
US10766903B2 (en) | 2020-09-08 |
KR20190069529A (en) | 2019-06-19 |
RU2019115115A (en) | 2020-11-24 |
CN110088096A (en) | 2019-08-02 |
CA3040805A1 (en) | 2018-04-26 |
ES2914284T3 (en) | 2022-06-08 |
IL266146A (en) | 2019-06-30 |
US20190256518A1 (en) | 2019-08-22 |
AU2017346516A1 (en) | 2019-05-02 |
BR112019007977A2 (en) | 2019-07-09 |
EP3529241B1 (en) | 2022-04-06 |
JP2022106953A (en) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201906795SA (en) | Novel plant cells, plants, and seeds | |
SG11201901506VA (en) | Distributed systems for the efficient production and use of microbe-based compositions | |
SG11201909777YA (en) | Modulatory polynucleotides | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201810509PA (en) | Anti-pd-l1 antibodies | |
SG11201804934PA (en) | Novel Compounds | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201808721YA (en) | Cell-free production of ribonucleic acid | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201804327TA (en) | Dual memory introspection for securing multiple network endpoints | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201804836RA (en) | Treatment of fibrosis | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900545TA (en) | Pharmaceutical compounds | |
SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
SG11201806330UA (en) | Positive type photosensitive siloxane composition | |
SG11201906686TA (en) | Ceramic material comprising a pseudo-cubic phase, a process for preparing and uses of the same | |
SG11201903193WA (en) | Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate |